sonelokimab

News

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake.

Views & Analysis

Inside MoonLake’s raid on Merck KGaA’s inflammatory disease ...

Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab.

News

MoonLake launches, licensing in Merck KGaA's Cosentyx challe...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KG

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Inside MoonLake’s raid on Merck KGaA’s inflammatory disease ...

MoonLake launches, licensing in Merck KGaA's Cosentyx challe...

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks